IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 26-50 out of 1332.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

Public Release: 22-Apr-2015
American Roentgen Ray Society (ARRS) 2015 Annual Meeting
Breast arterial calcification strong predictor of coronary artery calcification
In a study to ascertain whether breast arterial calcification (BAC) detected with digital mammography correlates to chest CT findings of coronary artery calcification (CAC), researchers have discovered a striking relationship between the two factors. In 76 percent of the study cohort, women who had a BAC score of 0 also had a CAC score of 0. As the BAC score increases, there is a concomitant increase in the CAC score.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 22-Apr-2015
Science Translational Medicine
Personalized cancer treatment
MIT researchers develop implantable device that could allow doctors to test cancer drugs in patients before prescribing chemotherapy.
Kibur Medical, NIH/National Cancer Institute

Contact: Sarah McDonnell
s_mcd@mit.edu
617-827-7637
Massachusetts Institute of Technology

Public Release: 22-Apr-2015
American Association for Cancer Research Annual Meeting 2015
Triple negative breast cancer in African-American women has distinct difference
What makes triple negative breast cancer more lethal in African-American women than white women or women of European descent? A new study reveals specific genetic alterations that appears to impact their prognosis and ultimately survival rates.
US Food and Drug Administration

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 22-Apr-2015
American Association for Cancer Research Annual Meeting 2015
FACC-29 gathers authenticated canine cancer cell lines for research and drug development
Members of the University of Colorado Cancer Center report at the American Association for Cancer Research Annual Meeting 2015 the assembly of a panel of validated canine cancer cell lines named the FACC-29, analogous to the NCI-60.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver

Public Release: 22-Apr-2015
New England Journal of Medicine
Cancer scan could remove need for radiotherapy for cured patients
A UK National Cancer Research Institute trial led from The University of Manchester and the Christie NHS Foundation Trust has suggested that in patients with early stage Hodgkin's lymphoma the late effects of radiotherapy could be reduced by using a scan to determine those who actually need it.
Leukemia and Lymphoma Research

Contact: Jamie Brown
jamie.brown@manchester.ac.uk
44-161-275-8383
University of Manchester

Public Release: 22-Apr-2015
Science Translational Medicine
Microinjection platform tests multiple cancer drugs in tumors, predicts systemic response
A newly developed technology for evaluating multiple cancer drugs or combinations while a tumor is still in a patient's body has been shown to accurately predict systemic response to the drugs, according to researchers at Fred Hutchinson Cancer Research Center, Presage Biosciences and Celgene. The patented technology, CIVO™, consists of an arrayed microinjection drug delivery device and quantitative analysis methodology tested in xenografted mouse models, canine patients and an ongoing first-in-human study.
Presage Biosciences

Contact: Kira Gordon
kira@proncall.com
646-243-4920
PR on Call

Public Release: 22-Apr-2015
Science Translational Medicine
A promising step forward toward a new treatment against cancer
The work of UCL researchers, published on April 22 in the prestigious scientific magazine Science Translational Medicine, allows taking into consideration new methods of immunotherapy against cancer, which could lead to an improvement of the efficiency of the current treatment methods.
WELBIO

Contact: Sophie Lucas
sophie.lucas@uclouvain.be
32-276-47474
Université catholique de Louvain

Public Release: 21-Apr-2015
Clinical Cancer Research
More detailed findings confirm that coffee protects against breast cancer recurrence
A number of research studies have shown that coffee helps to protect against breast cancer. A new study led by Lund University, has confirmed that coffee inhibits the growth of tumors and reduces the risk of recurrence in women who have been diagnosed with breast cancer and treated with the drug tamoxifen.

Contact: Ann Rosendahl
ann.rosendahl@med.lu.se
46-461-77567
Lund University

Public Release: 21-Apr-2015
American Roentgen Ray Society (ARRS) 2015 Annual Meeting
More than 85 percent of surgeons disregard USPSTF breast screening recommendation
The vast majority of surgeons continue to recommend that women 40 years old or older with an average risk for breast cancer be screened annually for the disease, despite a 2009 US Preventive Services Task Force recommendation that such women be screened biennially beginning at 50 years old and continuing through age 74.

Contact: Lissa D. Hurwitz
lhurwitz@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 21-Apr-2015
Proceedings of the National Academy of Sciences
When genes are expressed in reverse: Discovered a regulatory mechanism of antisense DNA
A study published by the Genetics and Cancer Biology group at Proceedings of the National Academy of Sciences provides new clues to understand the functions of antisense DNA and its alterations in cancer.

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 21-Apr-2015
American Association for Cancer Research Annual Meeting 2015
Trial shows benefit of 'BRCA-targeting' drug in prostate cancer
Men with prostate cancer benefit from treatment with the pioneering drug olaparib -- the first cancer drug to target inherited mutations -- according to the results of a major trial presented at the American Association of Cancer Research conference in Philadelphia.
Prostate Cancer Foundation, Stand Up To Cancer, Cancer Research UK, Prostate Cancer UK, Movember Foundation

Contact: Henry French
henry.french@icr.ac.uk
44-207-153-5582
Institute of Cancer Research

Public Release: 21-Apr-2015
Journal of National Cancer Institute
Childhood cancer survivors more likely to claim social security support as adults
Survivors of childhood cancer are five times more likely to have been enrolled on Social Security disability assistance than people without a cancer history.

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences

Public Release: 21-Apr-2015
Immunity
Protein identified that serves as a 'brake' on inflammation
Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis, colitis and other autoimmune disorders. St. Jude Children's Research Hospital scientists led the study which appears today in the scientific journal Immunity.
National Institutes of Health, ALSAC

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 21-Apr-2015
American Association for Cancer Research Annual Meeting 2015
Mayo Clinic researchers identify methylated DNA markers -- noninvasive cancer screen
A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample.

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 20-Apr-2015
American Journal of Hematology
Decreased red blood cell clearance predicts development and worsening of serious diseases
Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications.
NIH/National Institute for Diabetes and Kidney Disease, National Institutes of Health, Abbott Hematology

Contact: McKenzie Ridings
mridings@partners.org
617-726-0274
Massachusetts General Hospital

Public Release: 20-Apr-2015
Nature Chemistry
Happily ever after: Scientists arrange protein-nanoparticle marriage
University at Buffalo researchers have discovered a way to easily and effectively fasten proteins to nanoparticles -- essentially an arranged marriage -- by simply mixing them together. The biotechnology, described April 20 online in the journal Nature Chemistry, is in its infancy. But it already has shown promise for developing an HIV vaccine and as a way to target cancer cells.
National Institutes of Health

Contact: Cory Nealon
cmnealon@buffalo.edu
716-645-4614
University at Buffalo

Public Release: 20-Apr-2015
European Urology
Use of radiotherapy after prostate cancer surgery declining, despite evidence of benefit
Despite strong evidence and guidelines supporting its use, post-surgical radiation therapy for prostate cancer patients at risk of recurrence is declining in the United States.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 20-Apr-2015
American Association for Cancer Research Annual Meeting 2015
MD Anderson study seeks earlier ovarian cancer detection
Successful ovarian cancer treatment often relies on catching it early. A study at the University of Texas MD Anderson Cancer Center may help point to a new method for women at risk.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 20-Apr-2015
PLOS Computational Biology
New tactic targets brain tumors
Patients who are obese, diabetic or both have the highest incidence of brain tumors, and they offer a clue that insulin is a factor for some glioblastoma patients. But a new Rice University study suggests drugs tested on such tumors targeted the wrong molecules.
National Science Foundation

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 20-Apr-2015
Journal of Experimental Medicine
Study sheds new light on a crucial enzyme for the immune response
A new study by immunology researchers at the IRCM led by Javier M. Di Noia, Ph.D., sheds light on a mechanism affecting AID, a crucial enzyme for the immune response. The scientific breakthrough, published in the latest issue of The Journal of Experimental Medicine, could eventually improve the way we treat the common flu, as well as lymphoma and leukemia.
Canadian Institutes of Health Research, Cole Foundation, Fonds de recherche du Québec - Santé

Contact: Julie Langelier
julie.langelier@ircm.qc.ca
514-987-5555
Institut de recherches cliniques de Montreal

Public Release: 20-Apr-2015
Journal of Biological Chemistry
New signaling pathway discovered in HER2-positive breast cancer, and 2 powerful drug targets
A team at CSHL has published results of experiments that lay bare a previously unknown pathway activated in a highly lethal form of breast cancer. The pathway, they discovered, contains at least two potentially powerful drug targets, according to the team leader. The breast cancer type is called HER2-positive, and affects about one cancer patient in four.
National Institutes of Health, The Gladowksy Breast Cancer Foundation, The Don Monti Memorial Research Foundation, Hansen Memorial Foundation, West Islip Breast Cancer Coalition for Long Island, Glen Cove CARES, Find a Cure today (FACT), and others

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory

Public Release: 20-Apr-2015
American Association for Cancer Research Annual Meeting 2015
MD Anderson study points to potential new lung cancer therapy
New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 20-Apr-2015
Journal of Biological Chemistry
Two recent Notre Dame papers shed light on how breast cancer cells avoid death
Two new papers from the lab of Zach Schafer, Coleman Assistant Professor of Cancer Biology at the University of Notre Dame, offer insights into how breast cancer cells avoid anoikis, which is cell death induced by detachment from the extracellular matrix.

Contact: Zachary T. Schafer
zschafe1@nd.edu
574-631-0875
University of Notre Dame

Public Release: 20-Apr-2015
Nature Communications
Changes in cancer epigenome implicated in chemotherapy resistance and lymphoma relapse
Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings from Weill Cornell Medical College investigators indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin's lymphoma.

Contact: Jen Gundersen
jeg2034@med.cornell.edu
646-317-7401
Weill Cornell Medical College

Public Release: 20-Apr-2015
Nature Cell Biology
Breast tumor stiffness and metastasis risk linked by molecule's movement
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and poor prognosis. The study may inspire new approaches to predicting patient outcomes and halting tumor metastasis.
National Institutes of Health, US Department of Defense Breast Cancer Program, American Cancer Society, Howard Hughes Medical Institute, ARCS Foundation, Fondation pour la Recherche Médicale

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Showing releases 26-50 out of 1332.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!